EP4444319A4 - Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen - Google Patents
Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungenInfo
- Publication number
- EP4444319A4 EP4444319A4 EP22903713.0A EP22903713A EP4444319A4 EP 4444319 A4 EP4444319 A4 EP 4444319A4 EP 22903713 A EP22903713 A EP 22903713A EP 4444319 A4 EP4444319 A4 EP 4444319A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lactat
- intaker
- prevention
- transport
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141057554 | 2021-12-10 | ||
| PCT/IB2022/061996 WO2023105482A1 (en) | 2021-12-10 | 2022-12-09 | Citric acid cycle and lactate transport inhibitors for prevention and/or treatment of skin disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4444319A1 EP4444319A1 (de) | 2024-10-16 |
| EP4444319A4 true EP4444319A4 (de) | 2025-12-03 |
Family
ID=86729793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22903713.0A Pending EP4444319A4 (de) | 2021-12-10 | 2022-12-09 | Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4444319A4 (de) |
| WO (1) | WO2023105482A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025049554A1 (en) * | 2023-08-28 | 2025-03-06 | New York University | Hif1a or glut1 inhibition in inflammatory skin diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002051405A1 (en) * | 2000-12-27 | 2002-07-04 | Nactilus Ab | New clinical treatment |
| CN105287496A (zh) * | 2015-10-08 | 2016-02-03 | 北京大学第一医院 | 一种治疗鱼鳞病的药物组合物及其制备方法 |
| WO2016118842A1 (en) * | 2015-01-23 | 2016-07-28 | University Of Florida Research Foundation, Inc. | Treatment of lupus using metabolic modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003262515A1 (en) * | 2002-09-19 | 2004-04-08 | Nieland, John Mr | Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| CN103442705B (zh) * | 2011-01-11 | 2015-11-25 | 巴塞尔大学 | 用于治疗癌症和免疫抑制的昔洛舍平与线粒体抑制剂的组合 |
| WO2012097052A2 (en) * | 2011-01-11 | 2012-07-19 | Intertech Bio, Llc | Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases |
| AU2012237327B2 (en) * | 2011-04-01 | 2016-10-20 | Iasomai Ab | New combination comprising N-acetyl-L-cysteine and its use |
| WO2013138744A1 (en) * | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| CN106309458A (zh) * | 2016-07-28 | 2017-01-11 | 中南大学湘雅医院 | 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用 |
| FR3105222B1 (fr) * | 2019-12-20 | 2022-06-03 | Nunii Laboratoire | Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur |
-
2022
- 2022-12-09 WO PCT/IB2022/061996 patent/WO2023105482A1/en not_active Ceased
- 2022-12-09 EP EP22903713.0A patent/EP4444319A4/de active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002051405A1 (en) * | 2000-12-27 | 2002-07-04 | Nactilus Ab | New clinical treatment |
| WO2016118842A1 (en) * | 2015-01-23 | 2016-07-28 | University Of Florida Research Foundation, Inc. | Treatment of lupus using metabolic modulators |
| CN105287496A (zh) * | 2015-10-08 | 2016-02-03 | 北京大学第一医院 | 一种治疗鱼鳞病的药物组合物及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| OFMEISTER V ET AL: "Peptide Epitopes derived from tumor stroma-associated antigens CD105 and FAP alpha for cancer immunotherapy", JOURNAL OF INVESTIGATIVE DERMATOLOGY, ELSEVIER, vol. 125, no. 3, Suppl. S, 24 September 2005 (2005-09-24), pages A70, XP008099590, ISSN: 0022-202X * |
| REDONDO P ET AL: "Topical N-acetylcysteine for lamellar ichthyosis", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 354, no. 9193, 27 November 1999 (1999-11-27), pages 1880, XP004828125, DOI: 10.1016/S0140-6736(99)04245-2 * |
| XIAOYAN HUANG ET AL: "Membrane-enriched solute carrier family 2 member 1 (SLC2A1/GLUT1) in psoriatic keratinocytes confers sensitivity to 2-deoxy-D-glucose (2-DG) treatment", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 28, no. 2, 21 December 2018 (2018-12-21), pages 198 - 201, XP071778658, ISSN: 0906-6705, DOI: 10.1111/EXD.13850 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023105482A1 (en) | 2023-06-15 |
| EP4444319A1 (de) | 2024-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3672594A4 (de) | Kombinationsprodukt aus bcl-2-inhibitor und mdm2-inhibitor und verwendung davon zur prävention und/oder behandlung von krankheiten | |
| EP3900717C0 (de) | Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen | |
| EP4272759A4 (de) | Mittel zur prävention oder behandlung von entzündlichen erkrankungen und/oder schmerzerkrankungen | |
| EP4185272A4 (de) | Behandlung und prävention von erkrankungen im zusammenhang mit atemwegserkrankungen | |
| EP4094754C0 (de) | Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen | |
| EP4196127C0 (de) | Nicotinamid-mononukleotid-derivate zur behandlung und prävention von sichelzellkrankheit | |
| EP4438048A4 (de) | Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen | |
| EP4238567A4 (de) | Neuartige behandlung und prävention von erkrankungen im zusammenhang mit sarkopenie | |
| EP4444319A4 (de) | Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen | |
| EP4404939A4 (de) | Hygromycin a zur behandlung von krankheiten und infektionen | |
| EP4403182A4 (de) | Medikament zur behandlung und/oder prävention von krebs | |
| EP4017496C0 (de) | Formulierungen zur vorbeugung und/oder behandlung von peripherer neuropathie und deren assoziierten erkrankungen | |
| EP4119158A4 (de) | Medikament zur behandlung und/oder prävention von krebs | |
| EP4119160A4 (de) | Medikament zur behandlung und/oder prävention von krebs | |
| EP4183416A4 (de) | Mittel zur prävention oder behandlung von muskelerkrankungen | |
| EP4415737A4 (de) | Zusammensetzungen und verfahren zur behandlung von hauterkrankungen | |
| EP4499608A4 (de) | Indolizinderivate zur behandlung von trpm3-vermittelten erkrankungen | |
| EP4351618A4 (de) | Trem-2/dap-12-hemmer zur behandlung von lungenerkrankungen und -verletzungen und kombinationen davon | |
| EP4440567A4 (de) | Therapeutische targets und mittel zur behandlung von posttraumatischen stresserkrankungen | |
| EP4461296A4 (de) | Pharmazeutische zusammensetzung zur prävention und/oder behandlung von herzinsuffizienz | |
| EP4401738A4 (de) | Arzneimittel zur prävention und/oder behandlung des trockenen auges | |
| EP4267163A4 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| EP3534924A4 (de) | Zusammensetzung zur vorbeugung und/oder behandlung von herz-kreislauf-erkrankungen | |
| EP4378478A4 (de) | Medikament zur behandlung und/oder prävention von krebs | |
| EP4355320A4 (de) | Organonitro- und sulfoxyalkylorganonitroverbindungen zur verwendung bei der behandlung von medizinischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240709 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031700400 Ipc: A61K0031194000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20251104 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/194 20060101AFI20251029BHEP Ipc: A61K 31/7004 20060101ALI20251029BHEP Ipc: A61K 31/198 20060101ALI20251029BHEP Ipc: A61K 31/336 20060101ALI20251029BHEP Ipc: A61K 31/475 20060101ALI20251029BHEP Ipc: A61K 31/4995 20060101ALI20251029BHEP Ipc: A61K 31/548 20060101ALI20251029BHEP Ipc: A61P 17/00 20060101ALI20251029BHEP Ipc: A61P 17/06 20060101ALI20251029BHEP Ipc: A61P 17/14 20060101ALI20251029BHEP Ipc: C12Q 1/6869 20180101ALI20251029BHEP Ipc: C12Q 1/6883 20180101ALI20251029BHEP Ipc: A61K 31/404 20060101ALI20251029BHEP Ipc: A61K 31/437 20060101ALI20251029BHEP Ipc: A61K 31/519 20060101ALI20251029BHEP |